Roche Pharmaceutical Development and Sales Overview

Als NMES Continuous increase in pipeline breadth and depth All-time high for Ph III Als and industry-leading number of NMEs in the clinic Projects in Ph III & registration Record number of NMEs and Als (YTD Sep 2022) 18 Phase I 2 2% 8% Phase II 3% 10% 14 3 11% 13 13 38% 2 1 3% 2 62 29 11 3 11% 31% 1 65% 4 9 5 4 2 4 4 1 1 1 1 1 6% 10% Phase III 9% 1 8 7 5 5 LO 5 21% 3 56 57% HY 2017 HY 2018 HY 2019 HY 2020 HY 2021 YTD Sep 2022 4% 9% 38 40 39 41 43 53 NME=new molecular entity; Al-additional indication Oncology/Hematology Immunology Infectious Diseases Neuroscience Ophthalmology Other 12 Roche

View entire presentation